Clinicians who suspect their patients may have immune thrombocytopenia (ITP) should look for platelet autoantibodies both in the bloodstream and the bone marrow, new research suggests. "Diagnosing ITP ...
ITP (immune thrombocytopenia) is an autoimmune disorder where the body attacks its own blood platelets. This leads to a decrease in the number of platelets and consequently can cause a number of ...
Recently published Immune Thrombocytopenia Market Insights report includes a comprehensive understanding of current treatment ...
An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune pathophysiology of immune thrombocytopenia (ITP) by modulating B cells, ...
SAN DIEGO — Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase (BTK) inhibitor for patients with previously treated immune thrombocytopenia (ITP). In the LUNA ...
Another episode of The Pitt, another surprise diagnosis (at least it's not gonorrhea of the eye this time)! During this week's episode, the labs finally came back for Kylie, the young girl whom the ...
About half of people with ITP say the condition affects their emotional and psychological health, and about one-third of them say it causes them to feel self-conscious about their appearance. Moreover ...
BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...
Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale ...
Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to second-line eltrombopag prolonged time to treatment failure by more than 40%. Researchers ...
Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE ® (fostamatinib disodium hexahydrate) in Mexico, for the ...
The immune thrombocytopenia market is experiencing steady growth driven by increasing disease awareness and improved diagnosis rates. Advancements in targeted therapies, including thrombopoietin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results